1. Generics Bulletin
  2. >>Products
  3. >>Biosimilars

Evidence And Education Must Support US Biosimilars

Misinformation ‘Continues To Be A Challenge’, Acknowledges Cardinal’s Oskouei

 
• By Dave Wallace

In the second part of an exclusive interview with Generics Bulletin, Cardinal Health’s vice president of biosimilars, Sonia Oskouei, talks about the importance of real-world evidence and education in ensuring confidence in biosimilars, as well as the ongoing struggle against misinformation and the need for clarity over concepts such as interchangeability and unbranded biologics.

Wooden man pushing misinformation rock uphill
Misinformation “continues to be a challenge” for biosimilars • Source: GoodIdeas / Alamy Stock Photo

Real-world evidence and education are key tools that must be used to ensure confidence in biosimilars among US healthcare professionals, Cardinal Health’s vice president of biosimilars, Sonia Oskouei, has told Generics Bulletin in the second part of an exclusive interview.

Having looked ahead to upcoming opportunities for US biosimilars – including a potential global leadership role in ophthalmology – in the first part of the interview (see sidebar), Oskouei turned to some of the challenges to biosimilar uptake and how these could be addressed, including

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Biosimilars

More from Products

After Jazz, Hikma Agrees $50m Settlement For ‘Most’ Xyrem ‘Pay-For-Delay’ Claims

 
• By Dean Rudge

Hikma said it would admit no wrongdoing or liability after reaching a preliminary settlement agreement over illicit ‘pay-for-delay’ claims involving its US version of Xyrem “that protects the company’s interests and provides clarity to our stakeholders.”

CIOMS Welcomes Draft Report Feedback On The Inevitable Future Of AI In Pharmacovigilance

 
• By Urtė Fultinavičiūtė

Pharmacovigilance is a perfect rule-based and manual work-intensive playground for experimenting with AI. While some off-patent drug firms are already exploring new automation tools, regulation is lagging behind, leaving a gap for uncertainty.

Viatris Pens Aprepitant Settlement Agreement After Kabi Loses Initial Patent Case

 
• By Dean Rudge

Viatris will look to introduce generic versions of Heron Therapeutics’ aprepitant brands, Cinvanti and Aponvie, around three years before patent expiry after settling litigation with the originator. Other court cases remain ongoing.